Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Year range
2.
Nat Aging ; 3(1): 82-92, 2023 01.
Article in English | MEDLINE | ID: covidwho-2186116

ABSTRACT

Whether age-associated defects in T cells impact the immunogenicity and reactogenicity of mRNA vaccines remains unclear. Using a vaccinated cohort (n = 216), we demonstrated that older adults (aged ≥65 years) had fewer vaccine-induced spike-specific CD4+ T cells including CXCR3+ circulating follicular helper T cells and the TH1 subset of helper T cells after the first dose, which correlated with their lower peak IgG levels and fewer systemic adverse effects after the second dose, compared with younger adults. Moreover, spike-specific TH1 cells in older adults expressed higher levels of programmed cell death protein 1, a negative regulator of T cell activation, which was associated with low spike-specific CD8+ T cell responses. Thus, an inefficient CD4+ T cell response after the first dose may reduce the production of helper T cytokines, even after the second dose, thereby lowering humoral and cellular immunity and reducing systemic reactogenicity. Therefore, enhancing CD4+ T cell response following the first dose is key to improving vaccine efficacy in older adults.


Subject(s)
COVID-19 Vaccines , COVID-19 , Humans , Aged , COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Vaccination/adverse effects , Immunity, Cellular , CD4-Positive T-Lymphocytes
3.
JPRN; 06/05/2021; TrialID: JPRN-jRCT1050210015
Clinical Trial Register | ICTRP | ID: ictrp-JPRN-jRCT1050210015

ABSTRACT

Condition:

COVID-19
COVID-19;C01.748.214;COVID-19

Criteria:

Inclusion criteria: 1) Definite COVID-19 patients
2) Male or female >= 18 years of age
3) Under close observation or in-patient hosptalization
4) Signed written informed consent approved by the relevant Independent Ethics Committee

Exclusion criteria:

SELECTION OF CITATIONS
SEARCH DETAIL